Market closed · Next open: Monday 9:30 AM ET
Last update: Aug 28, 2026, 6:10 PM ET
Eli Lilly and Company
$1,172.86 0.28% today
Market Closed

Why Eli Lilly and Company (LLY) stock moved

Updated Aug 30, 2026

Eli Lilly and Company (LLY) shares fell 0.3% to $1,172.86 as of August 30, 2026, a slight decline from the prior close of $1,176.10. BestStocks flagged the session as a major change for LLY. Below, we break down what changed for LLY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

LLY fell 0.3% to $1172.86

LLY fell 0.3% in its latest session, moving from $1,176.10 to $1,172.86.

ActivitySector-Wide MoveWeak confidence
Rel. volume
0.8×
Below Avg
Vs peers
Top 3 of 7 peers
In Line With Peers
Market cap
$1.1T
New York Stock Exchange
Analyst target
$1342
+14.4% vs price
Price chart
Jul 30 – Aug 28
VVEFNVVNNNNV$1113$1198$1283Jul 30Aug 6Aug 14Aug 21Aug 28
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Eli Lilly and Company investors

For Eli Lilly and Company investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Eli Lilly surged +2.64% to $1145.17 following a blowout Q2 2026 earnings report (investor.lilly.com). Weighing against that: Negative session, down 0.3%; LLY declined 3.13% to $1191.42 intraday, despite a Yahoo Finance headline reporting Lilly hitting new highs alongside J&J and AbbVie. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in LLY's fundamentals. Wall Street's consensus price target sits at $1,341.63, implying +14.4% upside from $1,172.86. BestStocks rates the overall signal quality weak (38/100). With earnings roughly 60 days out, the next report is the most likely near-term test of the move.

LLY price reaction

LLY last traded at $1,172.86, down $3.24 (-0.28%) from the previous close of $1,176.10. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -0.5% over the same stretch, leaving LLY essentially in line with peers. Over the past month the stock has ranged between $1,115.68 and $1,280.34, and it currently sits about 35% of the way up that band.

Bullish and bearish analyst opinions on Eli Lilly and Company (LLY)

The consensus analyst price target on Eli Lilly and Company (LLY) is $1,341.63, 14.4% above the recent $1,172.86. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LLY line up.

The bullish case

  • Wall Street's consensus price target of $1,341.63 implies +14.4% upside from $1,172.86.
  • The Street's most bullish target is $1,500.00 (+27.9%).
  • Positive price momentum.
  • Eli Lilly surged +2.64% to $1145.17 following a blowout Q2 2026 earnings report (investor.lilly.com).

The bearish case

  • The most bearish analyst target is $1,135.00 (-3.2%).
  • Negative session, down 0.3%.
  • LLY declined 3.13% to $1191.42 intraday, despite a Yahoo Finance headline reporting Lilly hitting new highs alongside J&J and AbbVie.
  • LLY fell 3.20% to $1190.63 intraday despite a Yahoo Finance headline reporting "Lilly, J&J and AbbVie Hit New Highs." Volume is running at 1.08x expected levels for this point in the session.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $1342+14.4%
= 15 maintains
Truist Securities maintained Buy · 2026-08-07
SEC filings watch
10-Q2026-08-05
Quarterly financial results
medium
8-K2026-08-05
Material event — review for impact
high
8-K2026-05-20
Material event — review for impact
high
8-K2026-05-07
Material event — review for impact
high
Peer context
LLY-0.3%
UNH-0.5%
JNJ+0.9%
PFE-0.2%
ABBV-1.0%
MRK-0.9%

Previous notable changes for LLY

News2026-08-28-0.3%
FDA approves Mounjaro for cardiovascular risk reduction in type 2 diabetes patients.
News2026-08-27-1.1%
FDA cleared Lilly-Roche's Alzheimer's blood test, enabling early disease detection and potential market expansion.
News2026-08-26-3.6%
Eli Lilly and Roche received FDA approval for a blood test identifying Alzheimer's disease biomarkers.
News2026-08-25-1.1%
Analysis compares LLY's growth prospects and pipeline against competitor AbbVie for 2026 investment outlook.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 60 days
10-Q Filing (est.)
2026-11-04
Medium impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
High
from change events

Frequently asked questions about LLY

Why did Eli Lilly and Company (LLY) stock move?

LLY fell 0.3% to $1,172.86. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.

How much did LLY stock fall?

LLY lost 0.28% ($3.24) versus the prior close of $1,176.10, last trading at $1,172.86 on 0.8× average volume.

When is Eli Lilly and Company's next earnings date?

LLY's next earnings report is estimated for 2026-10-29 — about 60 days away.

What is the analyst price target for LLY?

The consensus analyst price target for LLY is $1,341.63, about 14.4% above the current $1,172.86. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 0 downgrades.

Is the LLY move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -0.5% against LLY's -0.3%. LLY ranks top 3 of 7 peers.

How BestStocks tracks LLY

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LLY-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for LLY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsCompany news feedsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.